-
With the continuous upgrading of the traditional Chinese medicine formula granule industry, pharmaceutical companies are facing stricter supervision
Time of Update: 2021-12-07
In addition, since November 1st, the Hebei Provincial Drug Administration, the Provincial Administration of Traditional Chinese Medicine, the Provincial Health Commission, and the Provincial Medical Insurance Bureau jointly issued the "Hebei Province Traditional Chinese Medicine Formula Granule Management Implementation Rules (Trial)" has also been officially implemented .
-
Medical insurance negotiations have ended, and the industry recommends focusing on investment opportunities in this area
Time of Update: 2021-12-07
In the case of more and more standardized clinical drug management, innovative drugs that enter the medical insurance catalog are expected to quickly achieve commercialization, which is especially good for business.
-
Jiangsu pharmaceutical company will win the first imitation of 400 million compound painkillers
Time of Update: 2021-12-07
According to data from Meinenet, the total sales of paracetamol and oxycodone tablets in China's public medical institutions and Chinese urban physical pharmacies in 2020 will be approximately 400 million yuan .
-
Recently, 29 batches of drugs failed to pass the random inspection
Time of Update: 2021-12-07
On November 10, the Guangdong Provincial Food and Drug Administration issued the "Notice on Drug Sampling Inspection Information (No.
On the same day, the Food and Drug Administration of Guangdong Province also issued a notice on drug sampling inspection information.
-
Wantai Bio-Nose Spray Covid-19 Vaccine Receives South Africa Phase Ⅲ Clinical Trial Approval
Time of Update: 2021-12-07
Recently, the nasal spray influenza virus carrier new crown pneumonia vaccine ("nasal spray new crown vaccine") developed by it in cooperation with Xiamen University and the University of Hong Kong has won Phase III issued by the South African Drug Administration.
-
The Chinese market has become a growth engine for foreign-funded companies, localized into a key word for multinational pharmaceutical companies
Time of Update: 2021-12-07
In such a wave of innovation, multinational pharmaceutical companies should follow the reform and development trend of China's medical industry, accelerate innovation strategies, and better integrate into the Chinese market .
-
The results of medical insurance negotiations may be announced at the end of November.
Time of Update: 2021-12-07
In this year's medical insurance negotiations, Bojian's three rare disease drugs, including noxinagen sodium, dimethyl fumarate, and fampridine, passed the initial formal review of the national medical insurance drug catalog adjustment and appeared at the negotiation site .
-
AI + drug research and development has become a new trend, multinational pharmaceutical companies accelerate their deployment in China
Time of Update: 2021-12-07
For example, on October 11, during the Shanghai Biomedical Industry Week, AstraZeneca announced that the global R&D China Center was officially completed after the upgrade, and the Shanghai International Life Science Innovation Park and the Medical Artificial Intelligence Innovation Center were officially opened simultaneously .
-
The medical device sector, the "turning" is coming?
Time of Update: 2021-12-07
According to the news on November 16, the medical device sector rose by 2% as a whole.
It can be seen that domestic medical device products are accelerating the pace of realizing import substitution .
-
Paragraph 4!
Time of Update: 2021-12-07
This is an open, single-arm, multi-center study aimed at evaluating the safety, tolerability, pharmacokinetic characteristics, and effectiveness of ICP-189 single-agent and combination therapy in patients with advanced solid tumors .
-
Resistance to EGFR-TKI!
Time of Update: 2021-12-06
At 7 pm on November 19th, Beijing time, at the 2021 European Society for Medical Oncology Asia Annual Meeting (ESMO Asia) Plenary, Professor Lu Shun from the Chest Hospital of Shanghai Jiaotong Univer
-
200 million contrast agents!
Time of Update: 2021-12-06
A few days ago, the official website of NMPA showed that Chia Tai Tianqing's gadolinium disodium injection passed the consistency evaluation of generic drugs, and it was the second company to review the product .
-
Roche terminates development of COVID-19 oral antiviral drug AT-527
Time of Update: 2021-12-06
A few days ago, Roche announced the abandonment of its COVID-19 drug cooperation with Atea Pharmaceuticals .
More than a year ago, Roche and Atea signed a $350 million cooperation agreement for the oral antiviral drug AT-527 .
-
The cell and gene therapy industry has a high boom, the industry is optimistic about the CGTCDMO track
Time of Update: 2021-12-06
With the continuous growth of the gene cell therapy market, this field is also favored by investors.
Under the influence of policies and capital, the prosperity of the cell and gene therapy industry is expected to continue, and the CGTCDMO track is also favored by the industry .
-
China's innovative drug research and development momentum is strong, but the "quality" needs to be improved
Time of Update: 2021-12-06
In addition to PD-1/PD-L1 inhibitors, in recent years, there are not a few pharmaceutical companies that have carried out clinical trials around popular targets of anti-tumor drugs such as VEGF, EGFR, and HER-2.
-
Kangtai Bio's oral five-valent reassortant rotavirus live attenuated vaccine was approved for clinical use
Time of Update: 2021-12-06
On November 17, Kangtai Biologics issued an announcement stating that the oral five-valent reassortant rotavirus live attenuated vaccine (Vero cells) developed by it and its wholly-owned subsidiary Mi
-
Next, how should pharmaceutical companies highlight their encirclement?
Time of Update: 2021-12-06
Invesco Great Wall Fund Manager pointed out that the general direction of the pharmaceutical industry policy has been very clear, and companies with continuous innovation capabilities and internationalization are expected to stand out .
-
EU approves Pfizer's fifth indication for oral JAK inhibitor tofacitinib
Time of Update: 2021-12-06
The results showed that the study reached the primary endpoint: at the 16th week of treatment, compared with the placebo group, the proportion of patients who achieved an ASAS20 response in the Xeljanz treatment group increased significantly (56.
-
The innovation of pharmaceutical companies has begun to roll in, and differentiated development will become the key to breaking the game
Time of Update: 2021-12-06
The PD-1 drugs of Hengrui Medicine, BeiGene, and Junshi Bio Qiqi also entered the medical insurance list through negotiations, and the annual treatment cost has been reduced to 50,000 yuan .
-
Pharmaceutical companies are vying to lay out the "hyperglycemic" track, Class 1 new hypoglycemic drugs may welcome a major outbreak
Time of Update: 2021-12-06
According to incomplete statistics, there are currently more than 50 domestically produced Class 1 new hypoglycemic drugs in the clinical application and above stage, 14 of which have entered the phase III clinical and above stage, concentrated in DPP-4, GLP-1, and SGLT-2.
